Open Access Open Access  Restricted Access Subscription Access

Indications, Mechanism of Action, Administration, Adverse Effects, Contra Indications, Relative Contra Indications and Toxicity MMR Vaccine

Srinivas G., Ramanjaneyulu D.V., Muralinath E., Guruprasad M., Sravani Pragna K., Manjari P., Sony Sharlet E., T. Nikhil, V. Yaswanth Sai, D. Kusuma Latha, Ch. Ramya Sudha, K. Sridevi, D. Gokul Shiva Balaji

Abstract


Measles-containing vaccines are accepted by the US Food and Drug Administration (FDA) and utilized for the routine immunization of children and adolescents. These vaccines are also highly recommended for adults born after 1970 who have not been immunized. Adults who were born prior to 1970 are typically considered to have developed a natural immunity to measles. In order to protect themselves from potential infection, vulnerable individuals, including healthcare workers, military people, and visitors from outside North America, should get the measles, mumps, and rubella (MMR) vaccine.

 

The MMR vaccine is a live attenuated combination vaccine formulated along with live attenuated viruses, making it a harmless, less-virulent version of the infectious agents it targets. This vaccination is designed to boost immunity and prevent infectious diseases like rubella, mumps, and measles. The MMR vaccination is highly effective due to its live attenuated nature, but it requires several doses to get full immunity. Additionally, as a post-exposure prophylactic, this vaccination is strongly advised, especially for certain patient populations. In order to help the interprofessional healthcare team members safely administer the MMR vaccine to patients, this activity provides an overview of the vaccine's indications, mechanism of action, administration, and notable adverse reactions based on a variety of patient populations and clinical settings.In order to improve patient outcomes by boosting MMR vaccination uptake and preventing related illnesses, this effort attempts to equip medical personnel with the fundamental understanding of vaccine administration.


Full Text:

PDF

References


Marin, M., Broder, K. R., Temte, J. L., Snider, D. E., Seward, J. F., & Centers for Disease Control and Prevention (CDC). (2010). Use of combination measles, mumps, rubella, and varicella vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports, 59(RR-3), 1–12.

McLean, H. Q., Fiebelkorn, A. P., Temte, J. L., Wallace, G. S., & Centers for Disease Control and Prevention. (2013). Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: Summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports, 62(RR-04), 1–34.

Strikas, R. A., & Advisory Committee on Immunization Practices (ACIP). (2015). ACIP recommended immunization schedules for persons aged 0 through 18 years—United States, 2015. MMWR Morbidity and Mortality Weekly Report, 64(4), 93–94.

National Institute of Child Health and Human Development. (2024, August 15). Drugs and Lactation Database (LactMed®): Measles-Mumps-Rubella Vaccine. https://www.ncbi.nlm.nih.gov/books/NBK501922/

Psarris, A., Sindos, M., Daskalakis, G., Chondrogianni, M. E., Panayiotou, S., Antsaklis, P., & Loutradis, D. (2019). Immunizations during pregnancy: How, when and why. European Journal of Obstetrics & Gynecology and Reproductive Biology, 240, 29–35.

Krow-Lucal, E., Marin, M., Shepersky, L., Bahta, L., Loehr, J., & Dooling, K. (2022). Measles, mumps, rubella vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices—United States, 2022. MMWR Morbidity and Mortality Weekly Report, 71(46), 1465–1470.

MMR-162 Study Group. (2018). Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: A phase III, randomized study. Human Vaccines & Immunotherapeutics, 14(12), 2921–2931.

Abu-Elyazeed, R., Jennings, W., Severance, R., Noss, M., Caplanusi, A., Povey, M., & Henry, O. (2018). Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study. Human Vaccines & Immunotherapeutics, 14(11), 2624–2631.

Danziger-Isakov, L., Kumar, D., & AST ID Community of Practice. (2019). Vaccination of solid organ transplant candidates and recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 33(9), e13563.

Niederer-Loher, A. (2016). [Vaccinations in pregnancy – Don’t miss the opportunity!]. Therapeutische Umschau, 73(5), 269–273.

France, E. K., Glanz, J., Xu, S., Hambidge, S., Yamasaki, K., Black, S. B., ... & Vaccine Safety Datalink Team. (2008). Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics, 121(3), e687–e692.

Aldecoa, I., Archilla, I., Herrero, L., Garcia, F., Torres, B., Gaig, C., Fernández, S., Marcos, M. Á., & Gelpi, E. (2020). Measles inclusion body encephalitis. Clinical Neuropathology, 39(4), 148–151.

Habib, M. A., Povey, M., Casabona, G., Singh, T., & Abu-Elyazeed, R. (2023). Clinical trials show similar safety outcomes including febrile convulsion rates for GSK's and Merck's measles-mumps-rubella (MMR) vaccines. Human Vaccines & Immunotherapeutics, 19(1), 2188852.

Leung, A. K., Hon, K. L., Leong, K. F., & Sergi, C. M. (2018). Measles: A disease often forgotten but not gone. Hong Kong Medical Journal, 24(5), 512–520.

Ma, S. J., Xiong, Y. Q., Jiang, L. N., & Chen, Q. (2015). Risk of febrile seizure after measles-mumps-rubella-varicella vaccine: A systematic review and meta-analysis. Vaccine, 33(31), 3636–3649.

Schmidle, P., Mehlich, J., Brockow, K., Darsow, U., Biedermann, T., & Eberlein, B. (2021). Gelatin-containing vaccines for varicella, zoster, measles, mumps, and rubella induce basophil activation in patients with alpha-gal syndrome. International Archives of Allergy and Immunology, 182(8), 716–722.

Di Pietrantonj, C., Rivetti, A., Marchione, P., Debalini, M. G., & Demicheli, V. (2020). Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database of Systematic Reviews, 2020(4), CD004407.

Moro, P. L., Arana, J., Marquez, P. L., Ng, C., Barash, F., Hibbs, B. F., & Cano, M. (2019). Is there any harm in administering extra doses of vaccine to a person? Excess doses of vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2007–2017. Vaccine, 37(28), 3730–3734.

Sanyaolu, A., Okorie, C., Marinkovic, A., Ayodele, O., Abbasi, A. F., Prakash, S., ... & Chan, H. (2019). Measles outbreak in unvaccinated and partially vaccinated children and adults in the United States and Canada (2018–2019): A narrative review of cases. Inquiry: A Journal of Medical Care Organization, Provision and Financing, 56, 46958019894098.

Spencer, J. P., Trondsen Pawlowski, R. H., & Thomas, S. (2017). Vaccine adverse events: Separating myth from reality. American Family Physician, 95(12), 786–794.


Refbacks

  • There are currently no refbacks.